Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Medical technology major Becton, Dickinson and Company (BDX - Analyst Report) and JDRF reported that together they are hastening the creation of new offerings that amalgamate Becton’s glucose monitoring and insulin infusion expertise. The latest 3-year agreement builds upon a pre-existing relationship between the two parties to tackle type 1 diabetes.

JDRF is the biggest charitable financier for research into type 1 diabetes. It aims to eventually eliminate type 1 diabetes. In 2012, JDRF provided over $110 million for type 1 diabetes research. It is at present the sponsor of $530 million in scientific study in 17 nations.    

Those suffering from type 1 diabetes use an insulin pump to receive insulin which requires usage of a catheter. They must also monitor the level of glucose by using a continuous glucose monitoring device, which again requires a catheter-type sensor.

BDX and JDRF will strive to create a solitary device which will carry out both functions, without requiring catheters. This capability to carry out separate metabolic processes in a systematic manner, while curtailing human interference, leads to the concept of an artificial pancreas.  

We remain cautious about Becton Dickinson due to the lack of major short-term catalysts. The rising demand for safety-needle products (with higher price points and margins) was the primary driver of the company’s past growth. This is not expected to continue, given that the U.S. market is already largely penetrated.

On the positive side, Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.

The stock retains a Zacks Rank #3 (Hold). We are more positive about other stocks. CONMED Corporation (CNMD - Analyst Report), Heartware International Inc. (HTWR - Snapshot Report) and The Cooper Companies Inc. (COO - Analyst Report) each carry a Zacks Rank #2 (Buy) and are expected to do well.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
SKECHERS USA SKX 38.53 +4.50%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDS ENLC 36.29 +1.60%